Related Experiment Video
Updated: Jul 17, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway
Robert J George1, Mark A Sturmoski, Shrikant Anant
1Washington University School of Medicine, Department of Internal Medicine, St. Louis, Missouri 63110, USA.
Abstract:
The anti-apoptotic effect of PGE(2) was examined in Jurkat cells (human T-cell leukemia) by incubation with PGE(2) (5 nM) prior to treatment with the cancer chemotherapeutic agent camptothecin. Apoptosis was evaluated by caspase-3 activity in cell extracts and flow cytometry of propidium iodide-labeled cells. Pre-incubation with PGE(2) reduced camptothecin-induced caspase activity by 30% and apoptosis by 35%, respectively. Pharmacological data demonstrate that the EP4 receptor is responsible for mediating the protection from camptothecin-induced apoptosis. Pre-treatment of the cells with the EP4 antagonist (EP4A) prior to PGE(2) and camptothecin abolished the increased survival effect of PGE(2). Specific inhibition of the downstream of PI3 kinase or AKT/protein kinase but not protein kinase A prevents the observed increase in cell survival elicited by PGE(2). These findings have critical implications regarding the mechanism and potential application of PGE(2) receptor specific inhibition in cancer therapy.
Insights
Prostaglandin E2 (PGE2) protects human T-cell leukemia cells from chemotherapy-induced apoptosis via the EP4 receptor. This suggests potential therapeutic strategies targeting PGE2 signaling in cancer treatment.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Prostaglandin E2 (PGE2) is implicated in various physiological and pathological processes, including cancer.
- Understanding the role of PGE2 in cancer cell survival is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the anti-apoptotic effects of PGE2 in human T-cell leukemia (Jurkat) cells.
- To elucidate the specific receptor and downstream signaling pathways involved in PGE2-mediated cytoprotection.
Main Methods:
- Jurkat cells were incubated with PGE2 (5 nM) before treatment with camptothecin.
- Apoptosis was assessed by measuring caspase-3 activity and using flow cytometry with propidium iodide staining.
- Pharmacological inhibitors of EP4 receptor, PI3 kinase, AKT/protein kinase, and protein kinase A were utilized.
Main Results:
- PGE2 pre-incubation significantly reduced camptothecin-induced caspase-3 activity by 30% and apoptosis by 35%.
- The EP4 receptor was identified as the mediator of PGE2's protective effect against camptothecin-induced apoptosis.
- Inhibition of PI3 kinase or AKT/protein kinase, but not protein kinase A, blocked the cell survival effect of PGE2.
Conclusions:
- PGE2 confers significant protection against chemotherapy-induced apoptosis in Jurkat cells.
- The EP4 receptor and the PI3K/AKT signaling pathway are critical for mediating PGE2's anti-apoptotic effects.
- Targeting EP4 receptor signaling presents a potential therapeutic avenue for enhancing cancer treatment efficacy.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
IP3/DAG Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
